Conditions: Opioid-Induced Bowel Dysfunction
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 437
Healthy volunteers: no

Brief summary:
The primary purpose of this study is to evaluate the efficacy and safety of lubiprostone administration in patients with opioid-induced bowel dysfunction (OBD).

Detailed description:

Arms:
arm 1: 0 mcg capsules twice daily (BID) arm 2: 24 mcg capsules twice daily (BID)

Interventions: intervention 1: Lubiprostone intervention 2: Placebo
Intervention descriptions: intervention 1: 24 mcg capsules twice daily (BID) intervention 2: 0 mcg capsules twice daily (BID)

Protocol document: